IARC Monographs evaluation of the carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus

The International Agency for Research on Cancer (IARC) has evaluated the carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus. The outcome of the assessment has been published in a summary article in The Lancet Oncology and will be described in detail in Volume 137 of the IARC Monographs, to be published in 2025.

Publication status

Published in section: IARC News

Publication date: 27 November, 2024, 13:44

Direct link: https://iarc.spherical.horse/news-events/iarc-monographs-evaluation-of-the-carcinogenicity-of-hydrochlorothiazide-voriconazole-and-tacrolimus/

Other news

View all

The potential important role of environmentally associated DNA methylation in childhood acute lymphoblastic leukaemia subtypes - OYA

In collaboration with the International Agency for Research on Cancer (IARC), scientists have unc...

25.09.2025

Launch of IARC@60 – a year of celebration to mark the 60th anniversary of IARC!

The International Agency for Research on Cancer (IARC) is pleased to announce that Volume 135 of ...

07.02.2025

IARC Monographs Volume 134: Aspartame, methyleugenol, and isoeugenol

The International Agency for Research on Cancer (IARC) is pleased to announce that Volume 134 of the...

04.10.2024